That's Interesting

That's interesting archive

That's Interesting

This report was created to develop an in-depth understanding of Māori health consumers' and health providers/practitioners' perspectives on shared decision-making, and make recommendations for a more equity focused Choosing Wisely campaign. Produced by the Council of Medical Colleges, Te Ohu Rata o Aotearoa, Anna Adcock, and David Tipene-Leach.

This open access article from NZ Doctor Rata Aotearoa weighs up the benefits and risks of the two oral antiviral medicines currently available for early treatment of COVID-19. Written by Linda Bryant and Leanne Te Karu. 

In this Goodfellow podcast episode, endocrinologist Ryan Paul discusses sick day management in patients with diabetes. 

This article explores the inequities experienced by Pacific peoples with gout and outlines a novel innovative intervention strategy to improve the uptake of urate-lowering therapy in this population. 

International Journal for Equity in Health. 

In this article from New Zealand Doctor Rata Aotearoa, Dr Lucy O'Hagen explores her own pro-equity care and the challenges that patients face. 

This report from Pharmac explores the data around Pacific peoples with gout. This report was developed to support people in the decisions they make to improve the management of gout, and enhance the well-being of Pacific peoples. 

This open access article explores cardiovascular risk in Aotearoa and highlights how continued focus on preventing and managing CVD, especially from the perspective of those experiencing inequities is needed. 

New Zealand Medical Journal 

Rosuvastatin is an HMG-CoA reductase inhibitor (statin) that reduces low-density lipoprotein cholesterol (LDL-C) levels. From 1 December 2021, it became fully funded for the management of cardiovascular disease and familial hypercholesterolaemia for patients meeting Special Authority criteria.

This Medcase describes the safe prescribing of rosuvastatin for the prevention of cardiovascular disease. 

Pharmac has made a decision around the supply of perindopril tablets.

This decision means that:

  • There will be no change for people currently on perindopril treatment.
  • Coversyl will remain the funded brand of perindopril tablets.
  • The price of perindopril 2mg and 4mg tablets will change from 1 January 2022.
  • A higher strength 8mg tablet will be funded in the future, subject to Medsafe approval.

The addition of the 8mg option will provide a similar opportunity for effective treatment with one tablet once a day, as previously possible with cilazapril.

Pharmac has today released the first of a series of reports investigating inequities in medicine access. The report looks specifically at prescribing and dispensing medicines for gout, estimating 10,400 more Māori need preventive treatment each year to achieve equity in access to these medicines.